This At-A-Glance Guide describes a treatment management approach based on recommendations from the 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.1 Step diagrams from the 2007 Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3) were updated with the new recommendations. The diagrams are intended to help clinicians integrate the new recommendations into clinical care, and are meant to assist, and not replace, clinical judgment or decision-making for individual patient management, with input from individuals with asthma about their preferences.

### AGES 0–4 YEARS: STEPWISE APPROACH FOR MANAGEMENT OF ASTHMA

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Intermittent Asthma</th>
<th>Management of Persistent Asthma in Individuals Ages 0–4 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preferred</strong></td>
<td>PRN SABA and At the start of RTI: Add short course daily ICS</td>
<td>Daily low-dose ICS and PRN SABA</td>
</tr>
<tr>
<td><strong>Alternative</strong></td>
<td>Daily montelukast* or Cromolyn,* and PRN SABA</td>
<td>Daily medium-dose ICS + montelukast* and PRN SABA</td>
</tr>
</tbody>
</table>

For children age 4 years only, see Step 3 and Step 4 on Management of Persistent Asthma in Individuals Ages 5–11 Years diagram.

### Assess Control
- **First check adherence, inhaler technique, environmental factors, and comorbid conditions.**
- **Step up** if needed; reassess in 4–6 weeks
- **Step down** if possible (if asthma is well controlled for at least 3 consecutive months)

Consult with asthma specialist if Step 3 or higher is required. Consider consultation at Step 2.

Control assessment is a key element of asthma care. This involves both impairment and risk. Use of objective measures, self-reported control, and health care utilization are complementary and should be employed on an ongoing basis, depending on the individual’s clinical situation.

**Abbreviations:** ICS, inhaled corticosteroid; LABA, long-acting beta₂-agonist; SABA, inhaled short-acting beta₂-agonist; RTI, respiratory tract infection; PRN, as needed

*Updated based on the 2020 guidelines.
*Cromolyn and montelukast were not considered for this update and/or have limited availability for use in the United States. The FDA issued a Boxed Warning for montelukast in March 2020.

## NOTES FOR INDIVIDUALS AGES 0–4 YEARS DIAGRAM

<table>
<thead>
<tr>
<th>Quick-relief medications</th>
<th>Each step: Assess environmental factors, provide patient education, and manage comorbidities ▲</th>
</tr>
</thead>
</table>
| • Use SABA as needed for symptoms. The intensity of treatment depends on severity of symptoms: up to 3 treatments at 20-minute intervals as needed. | • In individuals with sensitization (or symptoms) related to exposure to pests: conditionally recommend integrated pest management as a single or multicomponent allergen-specific mitigation intervention. ▲  
• In individuals with sensitization (or symptoms) related to exposure to identified indoor allergens, conditionally recommend a multi-component allergen-specific mitigation strategy. ▲  
• In individuals with sensitization (or symptoms) related to exposure to dust mites, conditionally recommend impermeable pillow/mattress covers only as part of a multicomponent allergen-specific mitigation intervention, but not as a single component intervention. ▲ |
| • Caution: Increasing use of SABA or use >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and may require a step up in treatment. | • Consider short course of oral systemic corticosteroid if exacerbation is severe or individual has history of previous severe exacerbations. |
| • Consider short course of oral systemic corticosteroid if exacerbation is severe or individual has history of previous severe exacerbations. | |

### Notes

• If clear benefit is not observed within 4–6 weeks and the medication technique and adherence are satisfactory, the clinician should consider adjusting therapy or alternative diagnoses.

### Abbreviations

EIB, exercise-induced bronchoconstriction; SABA, inhaled short-acting beta₂-agonist.  
▲ Updated based on the 2020 guidelines.  
† Refers to mice and cockroaches, which were specifically examined in the Agency for Healthcare Research and Quality systematic review.

## WHAT’S NEW (AGES 0–4 YEARS)

- **Step 1**: In children ages 0–4 years with recurrent wheezing, a short (7–10 day) course of daily ICS with as-needed SABA for quick-relief therapy is recommended starting at the onset of a respiratory tract infection.
  - Recurrent wheezing is defined as at least three episodes of wheezing triggered by apparent infection in their lifetime, or two episodes in the past year, and no symptoms between infections.
  - One regimen, used in two reviewed studies, is budesonide inhalation suspension, 1 mg twice daily for 7 days at the first sign of respiratory tract infection-associated symptoms.
  - The main benefit during respiratory tract infections is a reduction in exacerbations requiring systemic corticosteroids.
  - Caregivers can initiate intermittent ICS treatment at home without a visit to a health care provider when they have clear instructions.
  - This treatment could affect growth. Carefully monitor growth in children who use this treatment.

- **Steps 3 and 4**: For children age 4 years only with persistent asthma, see Steps 3 and 4 on Management of Persistent Asthma in Individuals Ages 5–11 Years.

- **Each step**:
  - Consider the severity of an individual’s asthma, the small potential benefit, and the extent of previous symptoms and exacerbations when recommending allergen mitigation interventions.
### AGES 5–11 YEARS: STEPWISE APPROACH FOR MANAGEMENT OF ASTHMA

<table>
<thead>
<tr>
<th>Treatment</th>
<th>STEP 1</th>
<th>STEP 2</th>
<th>STEP 3</th>
<th>STEP 4</th>
<th>STEP 5</th>
<th>STEP 6</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preferred</strong></td>
<td>PRN SABA</td>
<td>Daily low-dose ICS and PRN SABA</td>
<td>Daily and PRN combination low-dose ICS-formoterol</td>
<td>Daily and PRN combination medium-dose ICS-formoterol</td>
<td>Daily high-dose ICS-LABA and PRN SABA</td>
<td>Daily high-dose ICS-LABA + oral systemic corticosteroid and PRN SABA</td>
</tr>
<tr>
<td><strong>Alternative</strong></td>
<td>Daily LTRA,* or Cromolyn,* or Nedocromil,* or Theophylline,* and PRN SABA</td>
<td>Daily medium-dose ICS and PRN SABA or Daily low-dose ICS-LABA, or daily low-dose ICS + LTRA,* or daily low-dose ICS + Theophylline,* and PRN SABA</td>
<td>Daily medium-dose ICS-LABA and PRN SABA or Daily medium-dose ICS + LTRA* or daily medium-dose ICS + Theophylline,* and PRN SABA</td>
<td>Daily high-dose ICS + LTRA* or daily high-dose ICS + Theophylline,* and PRN SABA</td>
<td>Daily high-dose ICS + LTRA* + oral systemic corticosteroid or daily high-dose ICS + Theophylline* + oral systemic corticosteroid, and PRN SABA</td>
<td></td>
</tr>
</tbody>
</table>

Steps 2–4: Conditionally recommend the use of subcutaneous immunotherapy as an adjunct treatment to standard pharmacotherapy in individuals ≥ 5 years of age whose asthma is controlled at the initiation, build up, and maintenance phases of immunotherapy.

Assess Control

- First check adherence, inhaler technique, environmental factors, and comorbid conditions.
- **Step up** if needed; reassess in 2–6 weeks
- **Step down** if possible (if asthma is well controlled for at least 3 consecutive months)

Consult with asthma specialist if Step 4 or higher is required. Consider consultation at Step 3.

Control assessment is a key element of asthma care. This involves both impairment and risk. Use of objective measures, self-reported control, and health care utilization are complementary and should be employed on an ongoing basis, depending on the individual's clinical situation.

**Abbreviations:** ICS, inhaled corticosteroid; LABA, long-acting beta₂-agonist; LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting beta₂-agonist

* Updated based on the 2020 guidelines.

* Cromolyn, Nedocromil, LTRAs including montelukast, and Theophylline were not considered in this update and/or have limited availability for use in the United States, and/or have an increased risk of adverse consequences and need for monitoring that make their use less desirable. The FDA issued a Boxed Warning for montelukast in March 2020.

** Omalizumab is the only asthma biologic currently FDA-approved for this age range.
### NOTES FOR INDIVIDUALS AGES 5–11 YEARS DIAGRAM

<table>
<thead>
<tr>
<th>Quick-relief medications</th>
<th>Each step: Assess environmental factors, provide patient education, and manage comorbidities</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Use SABA as needed for symptoms. The intensity of treatment depends on severity of symptoms: up to 3 treatments at 20-minute intervals as needed.</td>
<td>• In individuals with sensitization (or symptoms) related to exposure to pests‡: conditionally recommend integrated pest management as a single or multicomponent allergen-specific mitigation intervention.</td>
</tr>
<tr>
<td>• In Steps 3 and 4, the preferred option includes the use of ICS-formoterol 1 to 2 puffs as needed up to a maximum total daily maintenance and rescue dose of 8 puffs (36 mcg).</td>
<td>• In individuals with sensitization (or symptoms) related to exposure to identified indoor allergens, conditionally recommend a multi-component allergen-specific mitigation strategy.</td>
</tr>
<tr>
<td>• Caution: Increasing use of SABA or use &gt;2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and may require a step up in treatment.</td>
<td>• In individuals with sensitization (or symptoms) related to exposure to dust mites, conditionally recommend impermeable pillow/mattress covers only as part of a multicomponent allergen-specific mitigation intervention, but not as a single component intervention.</td>
</tr>
</tbody>
</table>

### Notes

- The terms ICS-LABA and ICS-formoterol indicate combination therapy with both an ICS and a LABA, usually and preferably in a single inhaler.
- Where formoterol is specified in the steps, it is because the evidence is based on studies specific to formoterol.
- In individuals ages 5–11 years with persistent allergic asthma in which there is uncertainty in choosing, monitoring, or adjusting anti-inflammatory therapies based on history, clinical findings, and spirometry, FeNO measurement is conditionally recommended as part of an ongoing asthma monitoring and management strategy that includes frequent assessment.

### Abbreviations

- EIB (exercise-induced bronchoconstriction); FeNO (fractional exhaled nitric oxide); ICS (inhaled corticosteroid); LABA (long-acting beta2-agonist); SABA (inhaled short-acting beta2-agonist).
- Updated based on the 2020 guidelines.
- ‡ Refers to mice and cockroaches, which were specifically examined in the Agency for Healthcare Research and Quality systematic review.

### WHAT’S NEW (AGES 5–11 YEARS)

- For individuals with mild to moderate persistent asthma who are taking daily ICS treatment (likely adherent with prescribed daily ICS) as a controller, increasing the regular daily ICS dose for short periods is not recommended when symptoms increase or peak flow decreases.
- **Steps 2–4:** Subcutaneous immunotherapy (SCIT) is recommended as an adjunct treatment for individuals who have demonstrated allergic sensitization and evidence of worsening asthma symptoms after exposure to the relevant antigen or antigens.
  - ✓ Do not initiate, increase, or administer maintenance SCIT doses while individuals have asthma symptoms.
  - ✓ Do not administer SCIT in individuals with severe asthma.
- **Steps 3 and 4:** For individuals with moderate to severe persistent asthma already taking low- or medium-dose ICS, the preferred treatment is a single inhaler with ICS-formoterol (referred to as single maintenance and reliever therapy, or “SMART”) used both daily and as needed.
  - ✓ Individuals with a severe exacerbation in the prior year are particularly good candidates for SMART to reduce exacerbations.
  - ✓ Do not use ICS-formoterol as reliever therapy in individuals taking ICS-salmeterol as maintenance therapy.
  - ✓ Individuals whose asthma is uncontrolled on maintenance ICS-LABA with SABA as quick-relief therapy should receive the preferred SMART if possible before moving to a higher step of therapy.
  - ✓ In children ages 4–11 years, there may be a lower risk of growth suppression among those taking SMART versus daily higher-dose ICS treatment.
- **Steps 5 and 6:** Consider Omalizumab, the only FDA-approved asthma biologic for this age group.
- **Each step:**
  - ✓ Consider the severity of an individual’s asthma, the small potential benefit, and the extent of previous symptoms and exacerbations when recommending allergen mitigation interventions.
**Intermittent Asthma**

**Management of Persistent Asthma in Individuals Ages 12+ Years**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>STEP 1</th>
<th>STEP 2</th>
<th>STEP 3</th>
<th>STEP 4</th>
<th>STEP 5</th>
<th>STEP 6</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preferred</strong></td>
<td>PRN SABA</td>
<td>Daily low-dose ICS and PRN SABA or PRN concomitant ICS and SABA</td>
<td>Daily and PRN combination low-dose ICS-formoterol</td>
<td>Daily and PRN combination medium-dose ICS-formoterol</td>
<td>Daily medium-high dose ICS-LABA + LAMA and PRN SABA</td>
<td>Daily high-dose ICS-LABA + oral systemic corticosteroids + PRN SABA</td>
</tr>
<tr>
<td><strong>Alternative</strong></td>
<td>Daily LTRA* and PRN SABA or Cromolyn,* or Nedocromil,* or Zileuton,* or Theophylline,* and PRN SABA</td>
<td>Daily medium-dose ICS and PRN SABA or Daily low-dose ICS-LABA, or daily low-dose ICS + LAMA, or daily low-dose ICS + LTRA,* and PRN SABA</td>
<td>Daily medium-dose ICS-LABA or daily medium-dose ICS + LAMA, and PRN SABA</td>
<td>Daily medium-high dose ICS-LABA or daily high-dose ICS + LTRA,* and PRN SABA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Steps 2-4: Conditionally recommend the use of subcutaneous immunotherapy as an adjunct treatment to standard pharmacotherapy in individuals ≥ 5 years of age whose asthma is controlled at the initiation, build up, and maintenance phases of immunotherapy.

Consider adding Asthma Biologics (e.g., anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13)**

**Assess Control**

- First check adherence, inhaler technique, environmental factors, and comorbid conditions.
- **Step up** if needed; reassess in 2–6 weeks
- **Step down** if possible (if asthma is well controlled for at least 3 consecutive months)

Consult with asthma specialist if Step 4 or higher is required. Consider consultation at Step 3.

Control assessment is a key element of asthma care. This involves both impairment and risk. Use of objective measures, self-reported control, and health care utilization are complementary and should be employed on an ongoing basis, depending on the individual’s clinical situation.

**Abbreviations:** ICS, inhaled corticosteroid; LABA, long-acting beta₂-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting beta₂-agonist

* Updated based on the 2020 guidelines.
* Cromolyn, Nedocromil,LTRAs including Zileuton and montelukast, and Theophylline were not considered for this update, and/or have limited availability for use in the United States, and/or have an increased risk of adverse consequences and need for monitoring that make their use less desirable. The FDA issued a Boxed Warning for montelukast in March 2020.
** The AHRQ systematic reviews that informed this report did not include studies that examined the role of asthma biologics (e.g. anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13). Thus, this report does not contain specific recommendations for the use of biologics in asthma in Steps 5 and 6.
* Data on the use of LAMA therapy in individuals with severe persistent asthma (Step 6) were not included in the AHRQ systematic review and thus no recommendation is made.
NOTES FOR INDIVIDUALS AGES 12+ YEARS

Quick-relief medications

- Use SABA as needed for symptoms. The intensity of treatment depends on the severity of symptoms: up to 3 treatments at 20-minute intervals as needed.
- In steps 3 and 4, the preferred option includes the use of ICS-formoterol 1 to 2 puffs as needed up to a maximum total daily maintenance and rescue dose of 12 puffs (54 mcg).\^\footnote{Updated based on the 2020 guidelines.} 
- Caution: Increasing use of SABA or use >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and may require a step up in treatment.

Each step: Assess environmental factors, provide patient education, and manage comorbidities\footnote{\(\ddagger\) Refers to mice and cockroaches, which were specifically examined in the Agency for Healthcare Research and Quality systematic review.}

- In individuals with sensitization (or symptoms) related to exposure to pests\(\ddagger\): conditionally recommend integrated pest management as a single or multicomponent allergen-specific mitigation intervention.\footnote{Updated based on the 2020 guidelines.} 
- In individuals with sensitization (or symptoms) related to exposure to identified indoor allergens, conditionally recommend a multi-component allergen-specific mitigation strategy.
- In individuals with sensitization (or symptoms) related to exposure to dust mites, conditionally recommend impermeable pillow/mattress covers only as part of a multicomponent allergen-specific mitigation intervention, but not as a single component intervention.

Notes

- The terms ICS-LABA and ICS-formoterol indicate combination therapy with both an ICS and a LABA, usually and preferably in a single inhaler.
- Where formoterol is specified in the steps, it is because the evidence is based on studies specific to formoterol.
- In individuals ages 12 years and older with persistent allergic asthma in which there is uncertainty in choosing, monitoring, or adjusting anti-inflammatory therapies based on history, clinical findings, and spirometry, FeNO measurement is conditionally recommended as part of an ongoing asthma monitoring and management strategy that includes frequent assessment.
- Bronchial thermoplasty was evaluated in Step 6. The outcome was a conditional recommendation against the therapy.

Abbreviations

- EIB, exercise-induced bronchoconstriction; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; LABA, long-acting beta\(_2\)-agonist; SABA, inhaled short-acting beta\(_2\)-agonist.

WHAT’S NEW (AGES 12+ YEARS)

- For individuals with mild to moderate persistent asthma who are taking daily ICS treatment (likely adherent with prescribed daily ICS) as a controller, increasing the regular daily ICS dose for short periods is not recommended when symptoms increase or peak flow decreases.

- **Step 2:** For individuals with mild persistent asthma, either of the following two treatments are recommended as part of Step 2 therapy: 1) a daily low-dose ICS and as-needed SABA for quick-relief therapy, or 2) intermittent as-needed SABA and ICS used one after the other for worsening asthma.
  - One approach to intermittent therapy is two to four puffs of albuterol followed by 80–250 mcg of beclomethasone equivalent every 4 hours as needed for asthma symptoms.
  - Intermittent therapy can be initiated at home with regular provider follow-up to ensure that the intermittent regimen is still appropriate.
  - Individuals with either low or high perception of symptoms may not be good candidates for as-needed ICS therapy. Daily low-dose ICS with as-needed SABA may be preferred.

- **Steps 2–4:** Subcutaneous immunotherapy (SCIT) is recommended as an adjunct treatment for individuals who have demonstrated allergic sensitization and evidence of worsening asthma symptoms after exposure to the relevant antigen or antigens.
  - Do not initiate, increase, or administer maintenance SCIT doses while individuals have asthma symptoms.
  - Do not administer SCIT in individuals with severe asthma.

- **Steps 3 and 4:** For individuals with moderate to severe persistent asthma already taking low- or medium-dose ICS, the preferred treatment is a single inhaler with ICS-formoterol (referred to as single maintenance and reliever therapy, or “SMART”) used both daily and as needed.
  - Individuals with a severe exacerbation in the prior year are particularly good candidates for SMART to reduce exacerbations.
  - Do not use ICS-formoterol as reliever therapy in individuals taking ICS-salmeterol as maintenance therapy.
  - Individuals whose asthma is uncontrolled on maintenance ICS-LABA with SABA as quick-relief therapy should receive the preferred SMART if possible before moving to a higher step of therapy.

- Each step:
  - Consider the severity of an individual’s asthma, the small benefit, and the extent of previous symptoms and exacerbations when recommending allergen mitigation interventions.